Wednesday, February 05, 2020 9:47:29 AM
A bit of clarity. The Q3 2019 ER for 09/30/19 posted Total Revenue = C$43,386 ... the claim against HEXO was C$9.8M ...
23% of revenues is a big chunk but not fatal. Net probably went from black to red on this claim.
Everyone anticipated more cannabis 2.0 revenues in the 4th and 1st Q's.
The claim was probably over the 4th and 1st Q. We should see provisions for potential losses, but the revenue number should include the claim amount. Their accounting is not on a cash basis.
We should still see a revenue increase when the annual ER comes out with provisions in the "recent events" section explaining what happened with HEXO. There is still more than 60 days for a resolution to take place and a PR on that subject.
It would be helpful to get the final Australian permit that opens up all of the doors to the EU. A few new deals and or shipment announcements to the EU would be monumentally helpful.
23% of revenues is a big chunk but not fatal. Net probably went from black to red on this claim.
Everyone anticipated more cannabis 2.0 revenues in the 4th and 1st Q's.
The claim was probably over the 4th and 1st Q. We should see provisions for potential losses, but the revenue number should include the claim amount. Their accounting is not on a cash basis.
We should still see a revenue increase when the annual ER comes out with provisions in the "recent events" section explaining what happened with HEXO. There is still more than 60 days for a resolution to take place and a PR on that subject.
It would be helpful to get the final Australian permit that opens up all of the doors to the EU. A few new deals and or shipment announcements to the EU would be monumentally helpful.
Recent MEDIF News
- MediPharm Labs Positioned to Serve Growing U.S. Pharmaceutical and Clinical Research Demand Following Cannabis Rescheduling • GlobeNewswire Inc. • 04/27/2026 12:30:00 PM
- International Medical Sales Surge 43% as GMP Certified Producer Hits Global Growth Phase • AllPennyStocks.com • 03/30/2026 05:47:31 PM
- MediPharm Labs Reports Full Year & Fourth Quarter 2025 Results with Over 40% Annual Growth in International Medical Revenue • GlobeNewswire Inc. • 03/30/2026 11:45:00 AM
- MediPharm Labs Sets Date to Report Full Year and Fourth Quarter 2025 Financial Results • GlobeNewswire Inc. • 03/25/2026 11:05:48 PM
- MediPharm Labs Announces CEO Transition: David Pidduck to Step Down; CFO Greg Hunter Appointed Interim CEO • GlobeNewswire Inc. • 01/19/2026 01:00:00 PM
- MediPharm Labs to Enter New Market with Costa Rica Supply Agreement • GlobeNewswire Inc. • 01/13/2026 01:00:00 PM
- Historic U.S. Cannabis Rescheduling Unlocks Potential Growth Opportunities for MediPharm Labs, Backed by the Company's Suite of Licenses and Proven U.S. Clinical Trial Supply Experience • GlobeNewswire Inc. • 12/19/2025 01:45:00 PM
- MediPharm Labs Announces Board of Directors Changes: Shelley Potts Steps Down, Michael Bumby Returns • GlobeNewswire Inc. • 12/11/2025 01:30:00 AM
- MediPharm Labs Completes First Shipment to France • GlobeNewswire Inc. • 12/04/2025 01:40:00 PM
- MediPharm Announces Complete Dismissal of Defamation Action Initiated by Apollo, Nobul and Regan McGee Under Ontario Anti-SLAPP Law • GlobeNewswire Inc. • 11/14/2025 03:00:00 PM
- MediPharm Advances Global Reach in Q3 2025 with Double-Digit Revenue Growth and Strong International Medical Cannabis Gains • GlobeNewswire Inc. • 11/13/2025 01:00:00 PM
- MediPharm Labs Sets Date to Report Third Quarter 2025 Financial Results • GlobeNewswire Inc. • 11/10/2025 11:00:00 PM
